BEVERLY, MA – September 5, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company has been invited to present on the planned continued development of Brilacidin for Inflammatory Bowel Disease at the inaugural “IBD Innovate 2018” conference.
The day-long conference, hosted by the Crohn’s & Colitis Foundation and sponsored, in part, by Celgene Corporation, will be held on November 13, 2018, at the New York Academy of Medicine located in New York, NY. Participants will include diverse stakeholders interested in scientific advances and innovative programs in IBD, toward accelerating the introduction of novel products to address unmet medical needs in the treatment of chronic bowel diseases. Additional conference details can be found on the Crohn’s & Colitis Foundation website, or by clicking here.
The scientific poster—titled “Brilacidin for Inflammatory Bowel Disease: A Novel, Non-Corticosteroid, Non-Biologic Drug Candidate in Clinical Development”—to be presented at the conference will be available in the Events and Presentations section of the Company website on November 13, 2018.
“As an academic clinical investigator and practicing gastroenterologist, I believe that Brilacidin is an extremely promising mid-phase IBD drug candidate, particularly once formulated for oral delivery,” commented Francis A. Farraye, MD, MSc, Clinical Director, Section of Gastroenterology at Boston Medical Center, Professor of Medicine at Boston University School of Medicine and Scientific Advisor to Innovation Pharmaceuticals. “Brilacidin’s unique and broad mechanism-of-action—antibacterial and anti-inflammatory—is a potent combination, as infection and inflammation are both implicated in IBD pathogenesis and progression.”
About Brilacidin for IBD
Brilacidin is being developed as a novel, non-corticosteroid, non-biologic treatment, with formulation development plans including oral tablets for the treatment of Ulcerative Colitis and Crohn’s Disease, and foam and/or gel for the treatment of mild-to-moderate Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of IBD. As released previously, a majority of patients treated with Brilacidin administered via retention enema achieved Clinical Remission in a Phase 2, open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin for UP/UPS.
About Brilacidin
Brilacidin is Innovation Pharmaceuticals’ lead drug candidate in its defensin mimetic franchise. Modeled after Host Defense Proteins (HDPs), the “front-line” of defense in the immune system, it is a small, non-peptidic, synthetic molecule that kills pathogens swiftly and thoroughly. Just as importantly, Brilacidin also functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing. Due to its unique properties, the Company has studied Brilacidin’s effect on Oral Mucositis (under Fast Track designation) and on Ulcerative Proctitis/Proctosigmoiditis (UP/UPS) in Phase 2 trials. Brilacidin is also being developed under FDA’s Qualified Infectious Disease Product (QIDP) designation as an antibacterial product for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)—qualifying it for Fast Track and possible Priority FDA Review and a potential extra 5 years of United States market exclusivity upon drug approval.